Tumor Infiltrating Lymphocytes (TIL) trials for Lung cancer

All Tumor Infiltrating Lymphocytes (TIL) trials · All Lung cancer trials

Phase breakdown

Recruiting trials studying Tumor Infiltrating Lymphocytes (TIL) for Lung cancer

• Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC
  NCT05681780 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Lung Cancer
  NCT06538012 · Phase: Phase 1, Phase 2 · Ages: 16 Years to 90 Years · Sex: All (male and female) · 1 location
• TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Stomach and Esophageal Cancer
  NCT06532799 · Phase: Phase 1, Phase 2 · Ages: 16 Years to 90 Years · Sex: All (male and female) · 1 location

Common questions

How many trials study Tumor Infiltrating Lymphocytes (TIL) for Lung cancer?

3 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.